Loader

Pathways

PathWhiz ID Pathway Meta Data

PW128159

Pw128159 View Pathway
drug action

Thioridazine Dopamine Antagonist Action Pathway

Homo sapiens
Thioridazine is a trifluoro-methyl phenothiazine derivative. Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. Similar to other first-generation or typical antipsychotics, thioridazine is a medication used to treat schizophrenia. Other indications for use include other psychotic disorders, depressive disorders, pediatric behavioral disorders, and geriatric psychoneurotic manifestations. Positive symptoms are believed to manifest as a result of increased levels of dopamine in the mesolimbic pathway. More specifically, thioridazine blocks DA-2 receptors in the mesolimbic pathway, diminishing positive symptoms. Thioridazine is classified as a low potency first-generation antipsychotic, and as such, is relatively sedating. Thioridazine is a substrate of the hepatic enzyme CYP450 2D6 and is also an inhibitor of the same enzyme. The drug also exhibits activity at muscarinic receptors (most notably the M1 receptor), which is most likely the source of its anticholinergic effects (e.g., dry mouth, constipation, etc.), the alpha 1A adrenergic receptor (which may explain its association with orthostatic hypotension), the H1 histamine receptor (probably accounting for much of its sedating effect), and the hERG gene, which is likely responsible for its cardiotoxicity

PW144791

Pw144791 View Pathway
drug action

Thioridazine Drug Metabolism Action Pathway

Homo sapiens

PW128160

Pw128160 View Pathway
drug action

Thioridazine Serotonin Antagonist Action Pathway

Homo sapiens
Thioridazine is a trifluoro-methyl phenothiazine derivative. Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. Similar to other first-generation or typical antipsychotics, thioridazine is a medication used to treat schizophrenia. Other indications for use include other psychotic disorders, depressive disorders, pediatric behavioral disorders, and geriatric psychoneurotic manifestations. Positive symptoms are believed to manifest as a result of increased levels of dopamine in the mesolimbic pathway. More specifically, thioridazine blocks DA-2 receptors in the mesolimbic pathway, diminishing positive symptoms. Thioridazine is classified as a low potency first-generation antipsychotic, and as such, is relatively sedating. Thioridazine is a substrate of the hepatic enzyme CYP450 2D6 and is also an inhibitor of the same enzyme. The drug also exhibits activity at muscarinic receptors (most notably the M1 receptor), which is most likely the source of its anticholinergic effects (e.g., dry mouth, constipation, etc.), the alpha 1A adrenergic receptor (which may explain its association with orthostatic hypotension), the H1 histamine receptor (probably accounting for much of its sedating effect), and the hERG gene, which is likely responsible for its cardiotoxicity

PW123546

Pw123546 View Pathway
metabolic

Thiosulfate Disproportionation III

Pseudomonas aeruginosa
Thiosulfate sulfurtransferase (also known as rhodanese) can facilitate the transfer of a sulfur atom from sulfur donors to nucleophilic sulfur acceptors, and it has been found in many major phyla (prokaryotic and eukaryotic). The role of thiosulfate sulfurtransferase might be the detoxification of cyanide in both bacteria and mammals, or it might also involve in formation of prosthetic groups in iron-sulfur proteins. In this pathway, thiosulfate and hydrogen cyanide have been catalyzed by thiosulfate sulfurtransferase to form thiocyanate and sulfite. Sulfite is used in later sulfur metabolism.

PW002060

Pw002060 View Pathway
metabolic

Thiosulfate Disproportionation III

Escherichia coli
Thiosulfate sulfurtransferase (also known as rhodanese) can facilitate the transfer of a sulfur atom from sulfur donors to nucleophilic sulfur acceptors, and it has been found in many major phyla (prokaryotic and eukaryotic). The role of thiosulfate sulfurtransferase might be the detoxification of cyanide in both bacteria and mammals, or it might also involve in formation of prosthetic groups in iron-sulfur proteins. In this pathway, thiosulfate and hydrogen cyanide have been catalyzed by thiosulfate sulfurtransferase to form thiocyanate and sulfite. Sulfite is used in later sulfur metabolism.

PW146175

Pw146175 View Pathway
drug action

Thiosulfuric acid Drug Metabolism Action Pathway

Homo sapiens

PW132352

Pw132352 View Pathway
metabolic

Thiotepa Drug Metabolism

Homo sapiens
Thiotepa is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Thiotepa passes through the liver and is then excreted from the body mainly through the kidney.

PW145563

Pw145563 View Pathway
drug action

Thiotepa Drug Metabolism Action Pathway

Homo sapiens

PW128181

Pw128181 View Pathway
drug action

Thiothixene Dopamine Antagonist Action Pathway

Homo sapiens
Thiothixene is an antipsychotic of the thioxanthene series. Thiothixene acts as an antagonist (blocking agent) on different post-sysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects)

PW145486

Pw145486 View Pathway
drug action

Thiothixene Drug Metabolism Action Pathway

Homo sapiens